Somewhat Positive News Coverage Somewhat Unlikely to Affect Concert Pharmaceuticals (CNCE) Share Price
Media stories about Concert Pharmaceuticals (NASDAQ:CNCE) have been trending somewhat positive this week, Accern Sentiment reports. Accern scores the sentiment of press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Concert Pharmaceuticals earned a media sentiment score of 0.19 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 45.8008508693987 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Here are some of the headlines that may have effected Accern Sentiment’s rankings:
- Zacks Investment Research Upgrades Concert Pharmaceuticals, Inc. (CNCE) to “Buy” (americanbankingnews.com)
- Concert Pharmaceuticals, Inc. (CNCE) Downgraded by Zacks Investment Research to “Hold” (americanbankingnews.com)
- Concert Pharmaceuticals (CNCE) & Its Competitors Financial Analysis (americanbankingnews.com)
- When Exciting Breakthrough Treatments Come With Astronomical Price Tags (khn.org)
Concert Pharmaceuticals (CNCE) traded up 2.06% during mid-day trading on Monday, hitting $14.88. 115,081 shares of the company were exchanged. Concert Pharmaceuticals has a 12 month low of $7.11 and a 12 month high of $19.11. The stock’s market cap is $337.58 million. The firm has a 50 day moving average price of $14.61 and a 200 day moving average price of $14.82.
Concert Pharmaceuticals (NASDAQ:CNCE) last announced its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.58) EPS for the quarter, beating the consensus estimate of ($0.62) by $0.04. The business had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.20 million. Concert Pharmaceuticals had a negative return on equity of 61.98% and a negative net margin of 60,681.70%. Analysts anticipate that Concert Pharmaceuticals will post ($2.18) EPS for the current fiscal year.
CNCE has been the topic of a number of recent research reports. HC Wainwright initiated coverage on shares of Concert Pharmaceuticals in a research note on Monday, July 24th. They set a “buy” rating and a $20.00 price target on the stock. ValuEngine upgraded shares of Concert Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Stifel Nicolaus reiterated a “buy” rating and set a $30.00 price target (down from $31.00) on shares of Concert Pharmaceuticals in a research note on Monday, July 10th. Aegis reiterated a “buy” rating and set a $25.00 price target on shares of Concert Pharmaceuticals in a research note on Monday, June 12th. Finally, Zacks Investment Research upgraded shares of Concert Pharmaceuticals from a “hold” rating to a “buy” rating and set a $17.00 price target on the stock in a research note on Tuesday, August 29th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $24.60.
ILLEGAL ACTIVITY NOTICE: This report was first published by Daily Political and is owned by of Daily Political. If you are viewing this report on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark laws. The legal version of this report can be accessed at https://www.dailypolitical.com/2017/09/18/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-concert-pharmaceuticals-cnce-share-price.html.
In related news, insider Ryan Lynch sold 3,500 shares of the firm’s stock in a transaction dated Thursday, September 14th. The stock was sold at an average price of $14.51, for a total transaction of $50,785.00. Following the sale, the insider now directly owns 9,500 shares in the company, valued at approximately $137,845. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 15.30% of the company’s stock.
Concert Pharmaceuticals Company Profile
Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company’s deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas.
Receive News & Ratings for Concert Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.